Effect of renal denervation on glucose metabolism after a 12 month follow-up

Daniel Matous, Otakar Jiravský, Igor Nykl, Marian Branný

Background. Renal denervation is an invasive endovascular procedure using radiofrequency ablation of the renal arteries. This reduces renal sympathetic activity. However, the effect of renal denervation on glucose metabolism remains unclear.

Aim. To evaluate the relation between sympathetic activity and glucose metabolism.

Methods. We enrolled 51 patients with resistant hypertension who underwent renal denervation in our hospital from September 2011 to July 2013. We divided the patients into 4 subgroups: those with diabetes mellitus; those without diabetes mellitus; patients who had undergone bilateral denervation with at least 4 radiofrequency applications to each renal artery. The last subgroup of patients had fewer than 4 applications bilaterally or only unilateral application for anatomical or technical reasons. For all patients the Simplicity flex catheter (Medtronic) was used. Fasting glucose, glycated hemoglobin, albuminuria and C-peptide were measured before the procedure and after 12 months.

Results. In all patients (n = 51) fasting glucose levels significantly increased (from 7.4±2.0 mmol/L to 7.8±2.6 mmol/L; P = 0.032). Glycated hemoglobin increased slightly but not significantly (from 46.1±10.5 mmol/mol to 47.6±13.6 mmol/mol; P = 0.079). There were no significant changes in albuminuria (71.2±191.0 mg/L to 66.1±185.5 mg/L; P = 0.108) or C-peptide levels (1178±429 pmol/L to 1271±565 pmol/L; P = 0.098).

Conclusions. We found no effect of renal denervation on glucose metabolism after 12 months follow-up.

Key words: renal denervation, glucose metabolism, diabetes mellitus, sympathetic activity, compliance

INTRODUCTION

The vegetative nervous system plays an important role in the regulation of glucose metabolism.

Increased sympathetic activity causes hyperinsulinemia via β1 and β2 receptors, insulin resistance and hyperglycemia1. Insulin resistance affects glucose metabolism, is located in peripheral tissues, is limited to nonoxidative pathways of intracellular glucose disposal, and directly correlates with the severity of the hypertension2. There is a bidirectional relationship between sympathetic overactivity inducing insulin resistance and hyperinsulinemia producing sympathetic activation, thus initiating a vicious cycle1. Activation of the sympathetic nervous system contributes to insulin resistance4 and the metabolic syndrome and is associated with central obesity4 and risk of developing diabetes mellitus1. It has been confirmed that physiological hyperinsulinemia increases norepinephrine release from the forearm muscle in the normal human. Moreover, this response is more pronounced in patients with essential hypertension6. Although insulin itself exhibits sympathoexcitatory effects9,10, renal denervation allows us to determine the direct role of the sympathetic nervous system, without necessitating further systemic pharmacological interactions in mediating insulin resistance and its consequences. Selective denervation of renal sympathetic nerves has the potential to improve glucose metabolism and blood pressure control concurrently in patients with resistant hypertension in the absence of significant changes in body weight and alterations in lifestyle or antihypertensive medication11. Percutaneous renal denervation may represent the first nonpharmaceutical approach for treating insulin resistance and drug-resistant hypertension.

METHODS

We enrolled 51 patients with resistant hypertension who had undergone renal denervation in Podlesi Hospital Trinec, Czech Republic from September 2011 to July 2013 (Table 1). Table 1 shows the baseline characteristics. The majority of patients were male (n = 31, 61%); 25 (49%) patients had diabetes mellitus type 2. The diagnosis was confirmed as recommended by the American Diabetes Association12. The remaining 26 (51%) patients had no diabetes; 43 (84%) had undergone bilateral denervation with at least 4 applications of radiofrequency to each renal artery. The remaining 8 (16%) patients had fewer than 4 or unilateral applications for anatomical or technical reasons. Mean age was 59.7±11.4 years. On average, all patients (n = 51) were taking 5.4±1.8 antihypertensive drugs, with 36 (71%) receiving an angiotensin-converting enzyme inhibitor; 23 (45%) on an angiotensin II receptor blocker; 50 (98%) on diuretics; 35 (75%) taking β-blockers; 38 (76%) on calcium channel blockers; 29 (56%) receiving centrally acting sympatholytic agents and 18 (36%) taking aldosterone antagonists. One patient did not receive any

Received: December 17, 2014; Accepted with revision: May 28, 2015; Available online: June 11, 2015
http://dx.doi.org/10.5507/bp.2015.030

*AGEL Research and Training Institute - Trinec Branch, Cardiovascular Centre, Podlesi Hospital, Trinec, Czech Republic
Corresponding author: Daniel Matous, e-mail: daniel.matous@email.cz
diuretic due to intolerance. On average, all patients were taking 1.25±0.45 peroral antidiabetic medication. Insulin therapy was taken by 3 patients and peroral antidiabetics with insulin simultaneously was taken by 4 patients. Antidiabetic treatment (insulin, peroral antidiabetics or both) had changed in 4 patients during 12 month follow-up. Fasting glucose, glycated hemoglobin, albuminuria and C-peptide were measured before the procedure and after 12 months. The glucose values are expressed in millimols per liter, HbA1c, millimol per mol, albuminuria milligrams per liter and C peptide as pikomols per liter. For statistical comparison, the two-tailed Student t-test was used and P < 0.05 was regarded as significant. Data are presented as means ± standard error of the mean. All statistical analyses were performed with Microsoft Excell statistical software.

## RESULTS

In all patients (n=51) fasting glucose level significantly increased (from 7.4±2.0 mmol/L to 7.8±2.6 mmol/L; P = 0.032; Fig. 1A). Glycated hemoglobin increased nonsignificantly (from 46.1±10.5 mmol/mol to 47.6±13.6 mmol/mol; P = 0.079; Fig. 1B). There were no significant changes in albuminuria (71.2±191.0 mg/L to 66.1±185.5 mg/L; P = 0.108) or C-peptide level (1178±429 pmol/L to 1271±565 pmol/L; P = 0.098; Fig. 1D).

In patients with diabetes mellitus type 2 (n = 25; 49%) fasting glucose significantly increased (from 8.6±1.9 mmol/L to 9.5±2.7 mmol/L; P = 0.033). We found no significant changes in glycated hemoglobin levels (from 53.0±10.2 mmol/mol to 55.8±14.8 mmol/mol; P = 0.116), albuminuria (from 81.6±55.2 mg/L to 62.0±154.0 mg/L; P = 0.19) or C-peptide level (from 1236±463 pmol/L to 1421±686 pmol/L; P = 0.071); (Table 2).

In patients without diabetes mellitus (n = 26; 51%) there were no statistically significant changes in any parameter. Fasting glucose (from 6.0±0.7 mmol/L to 6.1±0.8 mmol/L; P = 0.38), glycated hemoglobin (from 38.9±4.1 mmol/mol to 39.4±4.6 mmol/mol; P = 0.171), albuminuria (from 60.7±225.2 mg/L to 70.0±213.7 mg/L; P = 0.157) and C-peptide (from 1116±390 pmol/L to 1128±380 pmol/L; P = 0.441); (Table 3).

In patients with bilateral denervation and at least 4 radiofrequency applications to each renal artery (n = 43; 84%) fasting glucose significantly increased (from 7.5±2.1 mmol/L to 8.1±2.8 mmol/L; P = 0.019). Glycated hemoglobin (from 46.6±10.7 mmol/mol to 48.5±14.3 mmol/mol; P = 0.065) and albuminuria (from 69.8±198.8 mg/L to 74.4±200.5 mg/L; P = 0.097); (Table 4).

| Table 1. Baseline patient characteristics, n = 51. |
|-----------------------------------------------|
| Age, y | 59.7 ± 11.4 |
| Sex (male), n (%) | 31 (60.7) |
| Type 2 diabetes mellitus, n (%) | 25 (49) |
| Bilateral denervation with at least 4 applications, n (%) | 43 (84) |
| Antihypertensive drugs | 5.4 ± 1.8 |
| Peroral antidiabetics, n | 1.25±0.45 |
| Patients on insulin, n (%) | 4 (8) |

| Table 2. Changes in glucose metabolism at 12 months in diabetes subgroup, n=25 (49%). |
|-----------------------------------------------|
| Before | After | P |
| Fasting glucose, mmol/L | 8.6±1.9 | 9.5±2.7 | 0.033 |
| Glycated hemoglobin, mmol/mol | 53.0±10.2 | 55.8±14.8 | 0.116 |
| Albuminuria, mg/L | 81.6±55.2 | 62.0±154.0 | 0.19 |
| C-peptide, pmol/L | 1236±463 | 1421±686 | 0.071 |

| Table 3. Changes in glucose metabolism at 12 months in non-diabetes subgroup, n=26 (51%). |
|-----------------------------------------------|
| Before | After | P |
| Fasting glucose, mmol/L | 6.0±0.7 | 6.1±0.8 | 0.38 |
| Glycated hemoglobin, mmol/mol | 38.9±4.1 | 39.4±4.6 | 0.171 |
| Albuminuria, mg/L | 60.7±225.2 | 70.0±213.7 | 0.157 |
| C-peptide, pmol/L | 1116±390 | 1128±380 | 0.441 |

| Table 4. Changes in glucose metabolism at 12 months in bilateral denervation and at least 4 applications to each renal artery subgroup, n=43 (84%). |
|-----------------------------------------------|
| Before | After | P |
| Fasting glucose, mmol/L | 7.5±2.1 | 8.1±2.8 | 0.019 |
| Glycated hemoglobin, mmol/mol | 46.6±10.7 | 48.5±14.3 | 0.065 |
| Albuminuria, mg/L | 69.8±198.8 | 74.4±200.5 | 0.097 |
| C-peptide, pmol/L | 1165±425 | 1313±587 | 0.013 |
Table 5. Changes in glucose metabolism at 12 months in unilateral or „incomplete” denervation subgroup, n=8 (16%).

|                      | Before         | After          | \(P\) |
|----------------------|----------------|----------------|-------|
| Fasting glucose, mmol/L | 6.5±0.9        | 6.3±1.2        | 0.19  |
| Glycated hemoglobin, mmol/mol | 43.4±9.8     | 43.0±8.5       | 0.424 |
| Albuminuria, mg/L     | 78.1±157.3     | 19.8±24.1      | 0.368 |
| C-peptide, pmol/L     | 1244±473       | 1029±359       | 0.036 |

![Fig. 1A. Changes in fasting glucose (mmol/L).](image1)

![Fig. 1B. Changes in glycated hemoglobin (mmol/mol).](image2)

![Fig. 1C. Changes in albuminuria (mg/L).](image3)

![Fig. 1D. Changes in C-peptide (pmol/L).](image4)

To 74.4±200.5 mg/L; \(P = 0.097\) increased but this was not significant. C-peptide significantly increased (from 1165±425 pmol/L to 1313±587 pmol/L; \(P = 0.013\); (Table 4).

In patients undergoing less than 4 applications or unilateral for anatomical or technical reasons (n = 8, 16%) there were no significant changes in fasting glucose level (from 6.5±0.9 mmol/L to 6.3±1.2 mmol/L; \(P = 0.19\)), glycated hemoglobin level (from 43.4±9.8 mmol/mol to 43.0±8.5 mmol/mol; \(P = 0.424\)) and albuminuria (from 78.1±157.3 mg/L to 19.8±24.1 mg/L; \(P = 0.368\)). We found a significantly reduction in C-peptide level (from 1244±473 pmol/L to 1029±359 pmol/L; \(P = 0.036\); (Table 5).

**DISCUSSION**

The data from Mahfoud’s pilot study show that renal nerve ablation substantially improves insulin sensitivity.
and glucose metabolism, in addition to significantly reducing blood pressure. Percutaneous renal denervation may represent the first nonpharmaceutical approach for treating insulin resistance and drug-resistant hypertension\(^{11}\). Unfortunately, in our population of resistant hypertensives we did not confirm this effect. Our study has some limitations. A major limitation is there is no evidence that the ablation was done correctly. Direct measurement of sympathetic activity is an invasive technique appropriate to the experiment. It was very difficult to obtain the permission of patients for repeating microneurography (muscle sympathetic nerve activity measurement). For this reason, we focused on delivering the highest quality of the RDN procedure: our intervention approach involved biplanar checking of correct anterior and posterior positions. In our sample 84% patients underwent standard RDN according to common protocol - i.e. bilateral denervation with at least 4 applications of radiofrequency to each renal artery (proximal, distal, anterior, posterior - controlled by biplane X-ray). Only 16% of patients underwent "incomplete" RFA. When we exclude the patients who had not had the "complete" procedure from the sample we obtained data which does not confirm the RDN influence on glucose metabolism. The others limitations may be the potential interaction with drug effects. In 4 patients we registered changes in peroral antidiabetic medication dosage or changes in dosage of insulin. A decrease in antihypertensive drugs that have been shown to influence insulin sensitivity (eg. β-blockers, diuretics, angiotensin-converting enzyme inhibitors) (ref.\(^ {13}\)) could also have had an impact on our results. Compliance in using medical therapy and diabetic regimen is undoubtedly also an important factor. Optimal compliance was reported in only 46% patients usings peroral antidiabetics\(^ {14}\) and more than 50% of patients with resistant hypertension are known to be nonadherent to medications\(^ {15}\). We found a relatively high level of non compliance to the antihypertensive medication in our patients (serum levels of antihypertensives drus). Thus, we can assume the same applies to peroral antidiabetic medication. Significant improvement in blood pressure control associated with improved compliance and adherence with therapy has been noted\(^ {16}\). One way to improving this is to use a fixed combination of antihypertensive drugs. A 29% significant increase in compliance or persistence with therapy is associated with the use of fixed-dose combinations of antihypertensive agents for hypertension. These findings are similar to the results of meta-analysis of the use of fixed-dose combination medications for various chronic diseases, such as diabetes mellitus, hypertension, and HIV (ref.\(^ {17}\)). The results of the Simplicity-3 trial are relevant. This first double blinded trial showed no significant reduction in systolic blood pressure in patients with resistant hypertension 6 months after renal-artery denervation compared with a sham control\(^ {18}\). The outlook for renal denervation is hence currently unclear. Further studies are necessary.

CONCLUSION

We found no effect of renal denervation on glucose metabolism after 12 month follow-up in any subgroup.

ACKNOWLEDGEMENTS

Author contributions: DM: literature search; DM, OJ: manuscript writing; OJ, MB: study design; DM, OJ, IN: data collection; DM: statistical analysis; DM: data interpretation; all authors: final revision.

Conflict of interest statement: None declared.

REFERENCES

1. Ganong WF. Review of Medical Physiology. 20th ed. New York: McGraw Hill, 2001.
2. Ferrannini E, Buzzigoli G, Bonadonna R, Giorico MA, Oleggini M, Graziaide L, Pedrinelli R, Brandi L, Bevilacqua S. Insulin resistance in essential hypertension. N Engl J Med 1987;317:370-7.
3. Mancia G, Bousquet P, Elghozi JL, Esler M, Grassi G, Julius S, Reid J, Van Zwieten PA. The sympathetic nervous system and the metabolit syndrome. J Hypertens 2007;25:909-20.
4. Masuo K, Mikami H, Ogihara T, Tuck ML. Sympathetic nerve hyperactivity precedes hyperinsulinemia and blood pressure elevation in a young, nonobese Japanese population. Am J Hypertens 1997;10:77-83.
5. Grassi G, Dell’Oro R, Quartì-Trevano F, Scopellitti F, Seravalle G, Paleari F, Gamba PL, Mancia G. Neuroadrenergic and reflex abnormalities in patients with metabolic syndrome. Diabetologia 2005;48:1359-65.
6. Grassi G, Dell’Oro R, Faccini A, Quartì Trevano F, Boilla GB, Mancia G. Effect of central and peripheral body fat distribution on sympathetic and baroreflex function in obese normotensives. J Hypertens. 2004;22:2363-9.
7. Huggett RJ, Scott EM, Gilbeby SG, Stoker JB, Mackintosh AF, Mary DA. Impact of type 2 diabetes mellitus on sympathetic neural mechanisms in hypertension. Circulation 2003;108:3097-101.
8. Lembo G, Napoli R, Capaldo B, Binda V, Iacurri G, Volpe M, Tramarin B, Sacca L. Abnormal sympathetic overactivity evoked by insulin in the skeletal muscle of patients with essential hypertension. J Clin Invest 1992;90:24-9.
9. Scherrer U, Sartori C. Insulin as a vascular and sympathoexcitatory hormone: implications for blood pressure regulation, insulin sensitivity, and cardiovascular morbidity. Circulation 1997;96:4104-13.
10. Bardgett ME, McCarthy JJ, Stocker SD. Glutamatergic receptor activation in the rostral ventrolateral medulla mediates the sympathoexcitatory response to hyperinsulinemia. Hypertension 2010;55:284-90.
11. Mahfoud F, Schlaich M, Kindermann I, et al. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation 2011; 123:1940-6.
12. International Expert Committee report on the role of the a1c assay in the diagnosis of diabetes. Diabetes Care 2009;32:1327-34.
13. Cooper-DeHoff RM, Pacanowski MA, Pepine CJ. Cardiovascular therapiies and associated glucose homeostasis: implications across the dysglycemia continuum. J Am Coll Cardiol 2009;53:28-34.
14. Guillausseau PJ. Influence of oral antidiabetic drugs compliance on metabolic control in type 2 diabetes. A survey in general practice. Diabetes Metab 2003;29(1):79-81.
15. Jung O, Gechter JL, Wunder C, et al. Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens 2013;31:766-74.
16. Burnier M. Medication adherence and persistence as the cornerstone of effective antihypertensive therapy. Am J Hypertens 2006;19:1190-6.
17. Bangalore S, Kamalakannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007;120:713-9.
18. Bhatt DL, Kandzari DE, O’Neill WW, D’Agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha-Singh K, Townsend RR, Bakris GL. A Controlled Trial of Renal Denervation for Resistant Hypertension. N Engl J Med 2014; 370:1393-401.